Abstract
Epigenetic alterations have been associated with several human diseases including Alzheimers disease (AD). AD is a complex neurodegenerative disease characterized by a progressive decline in cognitive functions, neuronal cell loss and by the presence of β amyloid (Aβ) plaques and neurofibrillary tangles (NFTs) in the cortex. Mutations in specific genes have been identified but can only explain a small percentage of the AD cases. The origins of the sporadic cases of AD are still not known but there is evidence for a role of epigenetics in the etiology of the disease. In this review we focus on discussing the roles of DNA methylation and hydroxymethylation in the development and potential treatment of AD. We discuss papers showing that there are alterations in methylated cytosine (5mC) levels in AD and also highlight the potential role of hydroxylated methylcytosine (5hmC) in the epigenetic regulation of brain gene expression and perhaps in AD. We discuss the potential influence of environmental factors, working through epigenetic mechanisms, on increasing the risk of developing AD and their potential in treating this major neurodegenerative disorder.
Keywords: Alzheimer's disease, DNA methylation, epigenetics, 5-methylcytosine, 5-hydroxymethylcytosine, environment, pronucleus, aging, neurons, oxidative stress
Current Pharmaceutical Design
Title: Epigenetics in Alzheimers Disease: a Focus on DNA Modifications
Volume: 17 Issue: 31
Author(s): Natacha Coppieters and Mike Dragunow
Affiliation:
Keywords: Alzheimer's disease, DNA methylation, epigenetics, 5-methylcytosine, 5-hydroxymethylcytosine, environment, pronucleus, aging, neurons, oxidative stress
Abstract: Epigenetic alterations have been associated with several human diseases including Alzheimers disease (AD). AD is a complex neurodegenerative disease characterized by a progressive decline in cognitive functions, neuronal cell loss and by the presence of β amyloid (Aβ) plaques and neurofibrillary tangles (NFTs) in the cortex. Mutations in specific genes have been identified but can only explain a small percentage of the AD cases. The origins of the sporadic cases of AD are still not known but there is evidence for a role of epigenetics in the etiology of the disease. In this review we focus on discussing the roles of DNA methylation and hydroxymethylation in the development and potential treatment of AD. We discuss papers showing that there are alterations in methylated cytosine (5mC) levels in AD and also highlight the potential role of hydroxylated methylcytosine (5hmC) in the epigenetic regulation of brain gene expression and perhaps in AD. We discuss the potential influence of environmental factors, working through epigenetic mechanisms, on increasing the risk of developing AD and their potential in treating this major neurodegenerative disorder.
Export Options
About this article
Cite this article as:
Coppieters Natacha and Dragunow Mike, Epigenetics in Alzheimers Disease: a Focus on DNA Modifications, Current Pharmaceutical Design 2011; 17 (31) . https://dx.doi.org/10.2174/138161211798072544
DOI https://dx.doi.org/10.2174/138161211798072544 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mitochondrial Physiology and Toxicity (Mitotoxicity); Importance for the Immune System, Programmed Cell Death and Cancer
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Tetracyclines: Drugs with Huge Therapeutic Potential
Mini-Reviews in Medicinal Chemistry Potential of Bone Marrow Stromal Cells in Applications for Neuro-Degenerative, Neuro-Traumatic and Muscle Degenerative Diseases
Current Neuropharmacology The Current View on the Helicase Activity of RNA Helicase A and Its Role in Gene Expression
Current Protein & Peptide Science Current Scenario of 1,4-Diazepines as Potent Biomolecules-A Mini Review
Mini-Reviews in Medicinal Chemistry Gene Therapy: Optimising DNA Delivery to the Nucleus
Current Drug Targets Neuroprotective Effects of Lutein in the Retina
Current Pharmaceutical Design Cerebral Amyloidoses: Molecular Pathways and Therapeutic Challenges
Current Medicinal Chemistry The Neurovascular Unit: Focus on the Regulation of Arterial Smooth Muscle Cells
Current Neurovascular Research Pharmacological Applications of Antioxidants: Lights and Shadows
Current Drug Targets Peroxynitrite-Driven Mechanisms in Diabetes and Insulin Resistance – the Latest Advances
Current Medicinal Chemistry Proteins of the Esterase Family: Patents for Some Proteins in Search of Metabolic Functions
Recent Patents on Biomarkers Transport Mechanisms at the Blood-Cerebrospinal-Fluid Barrier: Role of Megalin (LRP2)
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) New Challenges in CNS Repair: The Immune and Nervous Connection
Current Immunology Reviews (Discontinued) Syntheses and Evaluation of Asymmetric Curcumin Analogues as Potential Multifunctional Agents for the Treatment of Alzheimer’s Disease
Current Alzheimer Research The Role of Extracellular Adenosine in Chemical Neurotransmission in the Hippocampus and Basal Ganglia: Pharmacological and Clinical Aspects
Current Topics in Medicinal Chemistry Defects in RNA Metabolism links FTD and ALS Pathogenesis: TDP-43, FUS, and C9orf72
Current Enzyme Inhibition Recent Progress in Dendrimer-based Gene Delivery Systems
Current Organic Chemistry The Emerging Role of MicroRNA in Schizophrenia
CNS & Neurological Disorders - Drug Targets From Pharmacotherapy to Pathophysiology: Emerging Mechanisms of Apolipoprotein D in Psychiatric Disorders
Current Molecular Medicine